Vertex Pharmaceuticals (VRTX) Q4 FY25 earnings call: guidance and Q&A

What is the risk of hypogamma adverse events with pove and how might it impact the label?

Reshma Kewalramani stated that while BAFF APRIL inhibitors decrease IgG levels as part of their mechanism, the RUBY-3 IgAN study showed no serious adverse events (SAEs) of infection, regardless of IgG levels. Only one patient had IgG below 300mg, not associated with serious infection. Average IgG levels remained within the normal range (around 700mg). She concluded that the overall benefit-risk profile, including IgG levels, looks very good.

“But the important question you're asking is what does that mean, if anything, on safety? So the data that we've shown is RUBY-3, the 80-milligram RUBY-3 cohort that we showed at ASN in November, what you see there is there are actually no SAEs, none of infection.”

asked by Cory Kasimov · answered by Reshma Kewalramani

How is payer access for pove in renal diseases, given historical challenges in the category? Also, how does sweat chloride awareness and willingness to switch to ALYFTREK compare between the U.S. and Europe?

Duncan McKechnie noted that payer engagements for pove began in July 2025, with 74 engagements covering over 210 million lives, and conversations are progressing well. For ALYFTREK, physician understanding of sweat chloride's connection to CFTR function is similar in the U.S. and Europe. Willingness to switch in Europe is influenced by fewer liver monitoring requirements and rapid uptake in treatment-naive patients, such as 1,500 patients in Italy gaining access for the first time.

“Firstly, we started engaging with the payers in July last year. We've, at this point, had 74 engagements with multiple payers that cover over 210 million lives. And I would say those conversations are going extremely well.”

asked by Geoffrey Meacham · answered by Duncan J. McKechnie

What magnitude of proteinuria reduction is expected for pove in IgAN to be clinically differentiated?

Reshma Kewalramani referenced the RUBY-3 80-milligram IgAN results as the best analog for the upcoming RAINIER trial, given similar design and endpoints. In RUBY-3, the 36-week proteinuria data showed a 56% reduction. She emphasized that even small improvements in proteinuria are significant for patients on chronic therapy, as it can impact long-term outcomes over 20 years.

“In RUBY-3, the 36-week proteinuria data was a 56% reduction in proteinuria. I think it's important to also note that the proteinuria reduction is something that I believe will have -- I think you could think of it as compounding effect over time.”

asked by Tazeen Ahmad · answered by Reshma Kewalramani

What is the rationale for studying pove in gMG, and how will it differentiate in a crowded market?

Reshma Kewalramani highlighted gMG as a sizable B cell-mediated disease with limitations in current therapies, particularly the need for cyclical administration. She noted that a wild-type TACI study in China showed remarkable efficacy, suggesting the mechanism of action is promising. Pove, as an engineered fusion protein with better potency, binding affinity, pharmacokinetics, and tissue distribution, is expected to offer best-in-class potential. A Phase II dose-ranging study is planned for H1 2026.

“But what that wild-type TACI tells me is that by mechanism of action, it is something to really hold close. So then you translate that to pove. Pove is not a wild-type TACI. Pove is this engineered fusion protein, better potency, better binding affinity, better pharmacokinetics, better tissue distribution.”

asked by Evan Seigerman · answered by Reshma Kewalramani

What are the expected rates of anti-drug antibodies (ADA) for pove, and how will the AMKD Phase III results compare to Phase II, given the broader patient population?

Reshma Kewalramani stated that ADAs are expected with biologics, but concerns arise only if they impact efficacy (neutralizing antibodies) or safety. Based on RUBY-3 data, she does not expect ADAs to be of consequence for pove. For AMKD, she expects Phase III AMPLITUDE results to be very similar to Phase II, despite the Phase III primary endpoint being GFR slope and the broader AMKD patient definition, as the underlying disease (2 APOL1 alleles) is the same as the FSGS studied in Phase II.

“So net-net, I expect the results to be in line with Phase II. And I will reaffirm the time lines for data sharing tail end of this year, beginning of next.”

asked by Michael Yee · answered by Reshma Kewalramani

Can you comment on the blinded serious infection data from the RAINIER study? Also, how does the WuXi deal for a trispecific T cell engager fit into the portfolio relative to pove?

Reshma Kewalramani stated that the independent data safety monitoring committee (DSMB) for the RAINIER study has reviewed blinded and unblinded data and has not requested any changes, giving the study 'clean bills of health'. Regarding the WuXi deal, she kept specific indications under wraps but noted that the interest in trispecific engagers aligns with Vertex's serial innovation strategy for B cell-mediated diseases, complementing pove's role across various indications.

“They review the data in an ongoing fashion. And of course, they review blinded and unblinded data. They review everything because they are the DSMB, they have not asked us to change anything in the study, and they've given the study clean bills of health as it goes through.”

asked by Terence Flynn · answered by Reshma Kewalramani